doi:10.1016/j.dld.2024.05.021engSanz Segura, PatriciaGomollón, FernandoCasas, DiegoIborra, MarisaVela, MilagrosFernández-Clotet, AgnèsMuñoz, RoserGarcía de la Filia, IreneGarcía Prada, MaríaFerrer Rosique, Juan ÁngelGarcía, María Joséde Francisco, RuthArias, LaraBarrio, JesúsGuerra, IvánPonferrada, ÁngelGisbert, Javier P.Carrillo-Palau, MartaCalvet, XavierMárquez-Mosquera, LucíaGros, BeatrizCañete, FiorellaMonfort, DavidMadrigal Domínguez, Rosa EvaRoncero, ÓscarLaredo, VivianaMontoro, MiguelMuñoz, CarmenLópez-Cauce, BeatrizLorente, RufoFuentes Coronel, AnaVega, PabloMartín, DoloresPeña, ElenaVarela, PilarOlivares, SonsolesPajares, RamónLucendo, Alfredo J.Sesé, EvaBotella Mateu, BelénNos, PilarDomènech, EugeniGarcía-López, SantiagoPsoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort studyART-2024-139335Background some patients with inflammatory bowel disease (IBD) treated with antiTNF develop drug-induced psoriasis (antiTNF-IP). Several therapeutic strategies are possible. Aims to assess the management of antiTNF-IP in IBD, and its impact in both diseases. Methods patients with antiTNF-IP from ENEIDA registry were included. Therapeutic strategy was classified as continuing the same antiTNF, stopping antiTNF, switch to another antiTNF or swap to a non-antiTNF biologic. IP severity and IBD activity were assessed at baseline and 16, 32 and 54 weeks. Results 234 patients were included. At baseline, antiTNF-IP was moderate-severe in 60 % of them, and IBD was in remission in 80 %. Therapeutic strategy was associated to antiTNF-IP severity (p < 0.001). AntiTNF-IP improved at week 54 with all strategies, but continuing with the same antiTNF showed the worst results (p = 0.042). Among patients with IBD in remission, relapse was higher in those who stopped antiTNF (p = 0.025). In multivariate analysis, stopping antiTNF, trunk and palms and soles location were associated with antiTNF-IP remission; female sex and previous surgery in Crohn´s disease with IBD relapse. Conclusion skin lesions severity and IBD activity seem to determine antiTNF-IP management. Continuing antiTNF in mild antiTNF-IP, and swap to ustekinumab or switch to another antiTNF in moderate-severe cases, are suitable strategies.2024http://zaguan.unizar.es/record/13644610.1016/j.dld.2024.05.021http://zaguan.unizar.es/record/136446oai:zaguan.unizar.es:136446DIGESTIVE AND LIVER DISEASE 56, 12 (2024), 2060-2068by-nc-ndhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.esinfo:eu-repo/semantics/openAccess